Clinical Trial Update: Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether a bolus-only abciximab regimen sustains inhibition of platelet function over time in patients with acute coronary syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• ReoPro (abciximab)

Snippet

Sponsor: Università degli Studi di Ferrara | Conditions: Acute Coronary Syndrome | Phase 4 | Status: COMPLETED